Paweł Zalewski

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy

Sharlene Gill, Yoo‐Joung Ko, C. Cripps et al. · Journal of Clinical Oncology · 2016 · 291 citations

Medicine, Oncology, Pharmacotherapy +13

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025

Bernard Escudier, Robert J. Motzer, Padmanee Sharma et al. · European Urology · 2017 · 240 citations

Medicine, Oncology, Pharmacotherapy +13

European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (EUROMENE): Expert Consensus on the Diagnosis, Service Provision, and Care of People with ME/CFS in Europe

Luís Nacul, François‐Jérôme Authier, Carmen Scheibenbogen et al. · Medicina · 2021 · 196 citations · Full text

Public Affairs, Health Policy, Internal Medicine +12

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial

Bernard Escudier, M. Dror Michaelson, Robert J. Motzer et al. · British Journal of Cancer · 2014 · 102 citations · Full text

Medicine, Oncology, Pharmacology +12